Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
Author:
Funder
Japan Agency for Medical research and Development
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference24 articles.
1. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Girard;Ann Oncol : official journal of the European Society for Medical Oncology/ESMO,2015
2. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy;de Jong;Eur J Cancer,2008
3. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies;Engels;International journal of cancer Journal international du cancer,2003
4. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan;Kondo;Ann Thorac Surg,2003
5. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L;Hirai;Ann Oncol : official journal of the European Society for Medical Oncology/ESMO,2015
Cited by 89 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience;Thoracic Cancer;2023-12-27
2. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy;Cancers;2023-11-25
3. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101);Clinical Lung Cancer;2023-11
4. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis;Recent Patents on Anti-Cancer Drug Discovery;2023-11
5. Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review;Biomedicines;2023-10-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3